Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2018-03-20 Director's Dealing
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
Director's Dealing Classification · 100% confidence The document is a formal notification of share-based incentive allotments (share options and performance shares) to company executives (President & CEO and Board of Management members). This falls under the category of 'Director's Dealing' (DIRS) as it reports transactions/allotments involving managerial staff and securities, in compliance with the EU Market Abuse Regulation.
2018-03-20 English
Remuneration Information 2018
Remuneration Information Classification · 99% confidence The document text is a formal announcement in Danish detailing the allocation ('Tildeling') of stock options and performance shares to executive management and key employees. It specifies the number of options/shares, vesting conditions, exercise prices, valuation (using Black & Scholes), and accounting treatment (IFRS). This content directly relates to executive compensation and incentive plans, which falls under the scope of remuneration information or management disclosures regarding compensation structure. Among the provided codes, 'DEF 14A' is defined as 'Remuneration Information: Report detailing compensation for top executives and directors.' Although this is not a US DEF 14A filing, the subject matter aligns perfectly with remuneration disclosure. Since the document announces specific details about compensation awards rather than just a change in board members (MANG) or a general governance report (CGR), DEF 14A is the most appropriate classification for detailed executive compensation awards.
2018-03-20 English
Remuneration Information 2018
Remuneration Information Classification · 99% confidence The document explicitly details the 'Grant of share options and performance shares to members of the Board of Management and key employees'. This content relates directly to executive compensation, incentive plans, and equity awards, which falls under the scope of remuneration or management information. Reviewing the definitions: 1. DEF 14A (Remuneration Information) covers compensation for top executives and directors. 2. MANG (Board/Management Information) covers changes in the board/senior management. While this document details compensation (share options/performance shares), it is a specific announcement about the structure and grant of these incentives, rather than the full annual remuneration report (which DEF 14A usually represents). However, the core subject is executive compensation/incentives. Since the document is an announcement detailing the grant of equity incentives to management, it is most closely aligned with Remuneration Information (DEF 14A) or potentially Management Information (MANG). Given the detailed breakdown of option grants, exercise prices, and performance share values, it strongly relates to executive compensation disclosure. I will classify it as DEF 14A, as remuneration disclosure is the primary focus, even if it's not the formal proxy statement. If the document were solely about a change in a board member's position, MANG would be better. Since it is about their pay structure (equity grants), DEF 14A is the most specific fit among the options provided for compensation details.
2018-03-20 English
Grant of share options and performance shares to members of the Board of Management and key employees
Board/Management Information Classification · 95% confidence The document details the allocation of stock options and performance shares to the company's management and key employees. It outlines the specific terms of these incentive programs, including the number of options, vesting conditions, valuation methods (Black & Scholes), and the link to the company's remuneration guidelines approved at the AGM. While it discusses remuneration, it is a specific announcement of a grant/award of equity-based compensation rather than a full proxy statement (DEF 14A) or a director's personal dealing report (DIRS). Given the focus on executive and management compensation structures, it aligns best with the Remuneration Information category.
2018-03-20 Danish
Grant of share options and performance shares to members of the Board of Management and key employees
Remuneration Information Classification · 85% confidence The document is a company release detailing the grant of share options and performance shares to members of the Board of Management and key employees. While it discusses remuneration, it is not a formal proxy statement (DEF 14A) but rather a regulatory announcement of incentive plans. Since it details compensation for top executives and directors, it aligns best with the Remuneration Information category.
2018-03-20 English
Director's Dealing 2018
Director's Dealing Classification · 100% confidence The document explicitly references 'artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen)' and details transactions (Levering af aktier - Delivery of shares) conducted by persons discharging managerial responsibilities ('Adm. direktør', 'Direktionsmedlem'). This structure and regulatory citation are characteristic of insider transaction reporting, which falls under Director's Dealing (DIRS) in the provided schema, or potentially a general Regulatory Filing (RNS). Given the specific nature of reporting insider trades by management/directors, DIRS is the most precise fit.
2018-03-02 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.